Literature DB >> 10500817

Cellular drug resistance in childhood acute myeloid leukemia. A mini-review with emphasis on cell culture assays.

G J Kaspers1, C M Zwaan, R Pieters, A J Veerman.   

Abstract

Cellular drug resistance is an important limiting factor in the success of chemotherapy in childhood acute myeloid leukemia (AML). We summarize the results of the studies published sofar that have focussed on drug resistance in childhood AML, using cell culture assays. We also briefly report our own results of an ongoing study. Finally, potential applications of cellular drug resistance testing are discussed. It appears that cellular drug resistance differs between AML and acute lymphoblastic leukemia and between subgroups of AML patients, that AML cells of relapsed patients are more resistance to cytarabine than those of untreated patients, and that in vitro resistance to cytarabine and daunorubicin is related to a worse prognosis. However, more and larger studies are required to determine the exact role of cellular drug resistance testing in the treatment of childhood AML.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10500817

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours.

Authors:  I Hubeek; G J Peters; A J F Broekhuizen; I Talianidis; J Sigmond; B E S Gibson; U Creutzig; G Giaccone; G J L Kaspers
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

Review 2.  Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Authors:  Rosalyn D Blumenthal; David M Goldenberg
Journal:  Mol Biotechnol       Date:  2007-02       Impact factor: 2.695

3.  Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.

Authors:  Mahban Irandoust; Julian Alvarez Zarate; Isabelle Hubeek; Ellen M van Beek; Karin Schornagel; Aart J F Broekhuizen; Mercan Akyuz; Arjan A van de Loosdrecht; Ruud Delwel; Peter J Valk; Edwin Sonneveld; Pamela Kearns; Ursula Creutzig; Dirk Reinhardt; Eveline S J M de Bont; Eva A Coenen; Marry M van den Heuvel-Eibrink; C Michel Zwaan; Gertjan J L Kaspers; Jacqueline Cloos; Timo K van den Berg
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.